Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
April 02, 2024 14:36 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following...
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
December 18, 2023 09:00 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
December 04, 2023 09:00 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
November 13, 2023 09:00 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
November 09, 2023 14:45 ET
|
Harvard Apparatus Regenerative Technology, Inc.
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the...
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
May 31, 2023 09:15 ET
|
Biostage, Inc.
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs...
Biostage Appoints Ron Packard to Board of Directors
April 10, 2023 09:30 ET
|
Biostage, Inc.
HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Biostage Announces $6 Million Financing to Advance Clinical Trial
April 06, 2023 09:30 ET
|
Biostage, Inc.
HOLLISTON, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...